SG11201810137UA - Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof - Google Patents
Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereofInfo
- Publication number
- SG11201810137UA SG11201810137UA SG11201810137UA SG11201810137UA SG11201810137UA SG 11201810137U A SG11201810137U A SG 11201810137UA SG 11201810137U A SG11201810137U A SG 11201810137UA SG 11201810137U A SG11201810137U A SG 11201810137UA SG 11201810137U A SG11201810137U A SG 11201810137UA
- Authority
- SG
- Singapore
- Prior art keywords
- pro
- international
- pct
- diseases
- human neutrophil
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title abstract 3
- 239000000816 peptidomimetic Substances 0.000 title abstract 3
- 230000002849 elastaseinhibitory effect Effects 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title 1
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 102000052502 human ELANE Human genes 0.000 abstract 3
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000007775 late Effects 0.000 abstract 2
- 210000004072 lung Anatomy 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 239000008249 pharmaceutical aerosol Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000011623 Obstructive Lung disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization MD 1101/110 111010101111101011111 0 0111111111111111111111111111111111111111111 International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2017/207117 Al 07 December 2017 (07.12.2017) WIP0 I PCT (51) International Patent Classification: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, A61K 8/64 (2006.01) A61K 9/00 (2006.01) TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. A61K 38/12 (2006.01) CO7K 7/64 (2006.01) (84) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of regional protection available): ARIPO (BW, GH, PCT/EP2017/025156 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (22) International Filing Date: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 31 May 2017 (31.05.2017) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (25) Filing Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (26) Publication Language: English TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (30) Priority Data: 16020210.7 31 May 2016 (31.05.2016) EP Published: (71) Applicant: POLYPHOR AG [CH/CH]; Hegenheimermat- — with international search report (Art. 21(3)) tweg 125, 4123 Allschwil (CH). (72) Inventors: LUDIN, Christian; Im Drissel 24, 4104 Ober- wil (CH). KELLER, Manfred; Neunkirchner Str. 60, 81379 Mfinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, — = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, _ — HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, = Title: BETA-HAIRPIN PEPTIDOMIMETIC WITH ELASTASE INHIBITORY ACTIVITY AND AEROSOL DOSAGE FOR- = (54) = MS THEREOF = = Fig. 1 (57) : The present invention relates to pharmaceuti- cal aerosols comprising a 0-hairpin peptidomimetic of formu- la cyclo(-OctG-Glu-Thr-Ala-Ser-lle-Pro-Pro-Gln-Lys-Tyr- D Pro- = = Pro-), or a pharmaceutically acceptable salt thereof, having in- hibitory activity against human neutrophil elastase. It further re- lates to solid or liquid pharmaceutical compositions and kits for = * **** preparing and administering such aerosols. The invention can be v** -1- used for the prevention, management or treatment of pulmonary diseases, such as alpha-1 antitrypsin deficiency (AATD), cystic fi- brosis (CF), non-cystic fibrosis bronchiactasis (NCFB), or chronic — = • 1 obstructive pulmonary disease (COPD), or infections, or diseases, — 1-1 5 w or conditions of the lungs, being mediated by or resulting from human neutrophil elastase activity. Thus, the invention further re- IN lates to a pharmaceutical composition or a pharmaceutical aerosol 1-1 comprising the active compound cyclo(-OctG-Glu-Thr-Ala-Ser- 1-1 IN lle-Pro-Pro-Gln-Lys-Tyr- D Pro-Pro-), or any pharmaceutically ac- © ceptable salt thereof, for use in a method for the prevention, man- e , ' agement or treatment of diseases or conditions of the lungs being IN mediated by or resulting from human neutrophil elastase activity 1-1 0 ei Inhalation dosing in a subject. O
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16020210 | 2016-05-31 | ||
PCT/EP2017/025156 WO2017207117A1 (en) | 2016-05-31 | 2017-05-31 | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810137UA true SG11201810137UA (en) | 2018-12-28 |
Family
ID=56108445
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810138XA SG11201810138XA (en) | 2016-05-31 | 2017-05-31 | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
SG11201810137UA SG11201810137UA (en) | 2016-05-31 | 2017-05-31 | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
SG10202113280XA SG10202113280XA (en) | 2016-05-31 | 2017-05-31 | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810138XA SG11201810138XA (en) | 2016-05-31 | 2017-05-31 | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202113280XA SG10202113280XA (en) | 2016-05-31 | 2017-05-31 | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
Country Status (26)
Country | Link |
---|---|
US (3) | US11235024B2 (en) |
EP (2) | EP3463281B1 (en) |
JP (4) | JP7286319B6 (en) |
KR (2) | KR102511284B1 (en) |
CN (3) | CN116159024A (en) |
AU (2) | AU2017273507B2 (en) |
BR (2) | BR112018074551B1 (en) |
CA (2) | CA3024522A1 (en) |
CL (2) | CL2018003390A1 (en) |
DK (2) | DK3463281T3 (en) |
EA (2) | EA039603B1 (en) |
ES (2) | ES2927948T3 (en) |
HR (2) | HRP20221185T1 (en) |
HU (2) | HUE060393T2 (en) |
IL (2) | IL263114B2 (en) |
LT (2) | LT3463280T (en) |
MA (2) | MA45168A (en) |
MX (2) | MX2018014752A (en) |
PH (2) | PH12018502521A1 (en) |
PL (2) | PL3463281T3 (en) |
PT (2) | PT3463280T (en) |
RS (2) | RS63639B1 (en) |
SG (3) | SG11201810138XA (en) |
UA (2) | UA125899C2 (en) |
WO (2) | WO2017207118A1 (en) |
ZA (2) | ZA201807772B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL263114B2 (en) * | 2016-05-31 | 2023-12-01 | Spexis Ag | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
IL294959A (en) * | 2020-01-30 | 2022-09-01 | Vertex Pharma | Methods of treatment for alpha-1 antitrypsin deficiency |
AU2021383950A1 (en) * | 2020-11-23 | 2023-06-22 | Spexis Ag | Compositions of a beta-hairpin peptidomimetic and aerosol dosage forms thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2270290A1 (en) * | 1996-11-01 | 1998-05-14 | Xoma Corporation | Therapeutic uses of bpi protein products in cystic fibrosis patients |
WO2006079019A2 (en) * | 2005-01-21 | 2006-07-27 | Alza Corporation | Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion |
NZ556747A (en) | 2005-02-17 | 2009-09-25 | Polyphor Ltd | Template-fixed beta-hairpin peptidomimetics with protease inhibitory acitivity |
EP1712220A1 (en) * | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
MX2008010172A (en) | 2006-02-09 | 2009-09-07 | Pari Gmbh | Pulmonary delivery of alpha-i proteinase inhibitor. |
MX2008010222A (en) * | 2006-02-10 | 2008-10-17 | Pari Pharma Gmbh | Nebulised antibiotics for inhalation therapy. |
WO2008025560A1 (en) * | 2006-09-01 | 2008-03-06 | Pari Pharma Gmbh | Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy |
EP1927373B1 (en) * | 2006-11-30 | 2012-08-22 | PARI Pharma GmbH | Inhalation nebulizer |
ES2532667T3 (en) | 2011-09-12 | 2015-03-30 | Meiji Seika Pharma Co., Ltd. | Aqueous compositions containing arbekacin |
WO2015096672A1 (en) | 2013-12-23 | 2015-07-02 | 石家庄铁道大学 | Detection device |
JP6431486B2 (en) | 2013-12-26 | 2018-11-28 | 株式会社カネカ | Solar cell IV measuring method, solar cell IV measuring apparatus, solar cell manufacturing method, solar cell module manufacturing method, and solar cell module |
WO2015096873A1 (en) * | 2013-12-27 | 2015-07-02 | Polyphor Ag | Beta-hairpin peptidomimetics as selective elastase inhibitors |
EA034910B1 (en) | 2013-12-27 | 2020-04-06 | Полифор Аг | Beta-hairpin peptidomimetics as selective elastase inhibitors |
IL263114B2 (en) * | 2016-05-31 | 2023-12-01 | Spexis Ag | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
-
2017
- 2017-05-31 IL IL263114A patent/IL263114B2/en unknown
- 2017-05-31 MX MX2018014752A patent/MX2018014752A/en unknown
- 2017-05-31 JP JP2018562561A patent/JP7286319B6/en active Active
- 2017-05-31 SG SG11201810138XA patent/SG11201810138XA/en unknown
- 2017-05-31 HR HRP20221185TT patent/HRP20221185T1/en unknown
- 2017-05-31 LT LTEPPCT/EP2017/025156T patent/LT3463280T/en unknown
- 2017-05-31 RS RS20220922A patent/RS63639B1/en unknown
- 2017-05-31 CA CA3024522A patent/CA3024522A1/en active Pending
- 2017-05-31 ES ES17733737T patent/ES2927948T3/en active Active
- 2017-05-31 SG SG11201810137UA patent/SG11201810137UA/en unknown
- 2017-05-31 DK DK17733738.3T patent/DK3463281T3/en active
- 2017-05-31 RS RS20220923A patent/RS63622B1/en unknown
- 2017-05-31 BR BR112018074551-0A patent/BR112018074551B1/en active IP Right Grant
- 2017-05-31 PL PL17733738.3T patent/PL3463281T3/en unknown
- 2017-05-31 BR BR112018074532-4A patent/BR112018074532B1/en active IP Right Grant
- 2017-05-31 PL PL17733737.5T patent/PL3463280T3/en unknown
- 2017-05-31 KR KR1020187036055A patent/KR102511284B1/en active IP Right Grant
- 2017-05-31 PT PT177337375T patent/PT3463280T/en unknown
- 2017-05-31 AU AU2017273507A patent/AU2017273507B2/en active Active
- 2017-05-31 EP EP17733738.3A patent/EP3463281B1/en active Active
- 2017-05-31 US US16/305,714 patent/US11235024B2/en active Active
- 2017-05-31 KR KR1020187036054A patent/KR102480800B1/en active IP Right Grant
- 2017-05-31 EP EP17733737.5A patent/EP3463280B1/en active Active
- 2017-05-31 EA EA201892818A patent/EA039603B1/en unknown
- 2017-05-31 WO PCT/EP2017/025157 patent/WO2017207118A1/en unknown
- 2017-05-31 EA EA201892819A patent/EA201892819A1/en unknown
- 2017-05-31 MA MA045168A patent/MA45168A/en unknown
- 2017-05-31 JP JP2018562549A patent/JP2019523222A/en active Pending
- 2017-05-31 WO PCT/EP2017/025156 patent/WO2017207117A1/en unknown
- 2017-05-31 LT LTEPPCT/EP2017/025157T patent/LT3463281T/en unknown
- 2017-05-31 CN CN202211636345.7A patent/CN116159024A/en active Pending
- 2017-05-31 SG SG10202113280XA patent/SG10202113280XA/en unknown
- 2017-05-31 HR HRP20221194TT patent/HRP20221194T1/en unknown
- 2017-05-31 CN CN201780033187.7A patent/CN109195580A/en active Pending
- 2017-05-31 IL IL263112A patent/IL263112B2/en unknown
- 2017-05-31 CN CN201780033188.1A patent/CN109310613A/en active Pending
- 2017-05-31 HU HUE17733738A patent/HUE060393T2/en unknown
- 2017-05-31 ES ES17733738T patent/ES2928050T3/en active Active
- 2017-05-31 PT PT177337383T patent/PT3463281T/en unknown
- 2017-05-31 AU AU2017273508A patent/AU2017273508B2/en active Active
- 2017-05-31 UA UAA201812929A patent/UA125899C2/en unknown
- 2017-05-31 MX MX2018014425A patent/MX2018014425A/en unknown
- 2017-05-31 MA MA045167A patent/MA45167A/en unknown
- 2017-05-31 CA CA3024521A patent/CA3024521C/en active Active
- 2017-05-31 US US16/305,518 patent/US11235023B2/en active Active
- 2017-05-31 UA UAA201812930A patent/UA125900C2/en unknown
- 2017-05-31 HU HUE17733737A patent/HUE060119T2/en unknown
- 2017-05-31 DK DK17733737.5T patent/DK3463280T3/en active
-
2018
- 2018-11-19 ZA ZA2018/07772A patent/ZA201807772B/en unknown
- 2018-11-19 ZA ZA2018/07773A patent/ZA201807773B/en unknown
- 2018-11-28 CL CL2018003390A patent/CL2018003390A1/en unknown
- 2018-11-28 CL CL2018003391A patent/CL2018003391A1/en unknown
- 2018-11-29 PH PH12018502521A patent/PH12018502521A1/en unknown
- 2018-11-29 PH PH12018502522A patent/PH12018502522A1/en unknown
-
2021
- 2021-10-06 US US17/495,137 patent/US11844823B2/en active Active
-
2022
- 2022-01-04 JP JP2022000083A patent/JP2022078013A/en active Pending
- 2022-10-20 JP JP2022168582A patent/JP2023017793A/en not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907034PA (en) | Methods of treating influenza | |
SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
SG11201900471VA (en) | Combination therapy for copd | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
SG11201807963WA (en) | Compositions useful in the prevention and/or treatment of disorders of the oral cavity, upper airways and esophagus | |
SG11201809702SA (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
SG11201810137UA (en) | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof | |
SG11201907217RA (en) | Pharmaceutical combinations for treating cancer | |
SG11201901070YA (en) | Formulations for oral administration of active agents | |
SG11201808650QA (en) | Methods of treating ocular conditions | |
SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor | |
SG11201809494VA (en) | Pharmaceutical composition comprising eteplirsen |